M. Docteur PIERRE LE BLAY
✨ Profil synthétique
IA · 29/04/2026Le Docteur Pierre Le Blay est un rhumatologue libéral à Montpellier, avec une activité de recherche centrée sur les maladies auto-immunes et inflammatoires. Ses travaux portent notamment sur la polyarthrite rhumatoïde, le lupus érythémateux systémique et les fièvres auto-inflammatoires. Avec un h-index de 8 et 22 publications, il a également étudié les biothérapies et les essais cliniques dans le domaine de la rhumatologie.
Expertises présumées
- Polyarthrite rhumatoïde
- Lupus érythémateux systémique
- Fièvres auto-inflammatoires
- Arthrite juvénile
- Biothérapies non-anti-TNF
- Thérapies anti-TNF
- Essais cliniques en rhumatologie
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
9
h articles cités ≥ h fois chacun. Un h de 9 = 9 publications avec 9+ citations.
Citations
302
Publications
23
i10-index
9
Thématiques principales
- Rheumatoid Arthritis Research and Therapies ×12
- Autoimmune and Inflammatory Disorders Research ×5
- Systemic Lupus Erythematosus Research ×3
- Monoclonal and Polyclonal Antibodies Research ×3
- Psoriasis: Treatment and Pathogenesis ×2
Affiliations FR : Inserm · Inserm · Université de Montpellier
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis
2021ArticleRheumatology
Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
2020ArticleBMC Rheumatology
Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD
2017ArticleJournal of Rheumatology
Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis
2017ArticleJoint Bone Spine
Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for the self-assessment of rheumatoid arthritis disease activity
2016ArticleRheumatology
Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study
2015ArticleArthritis & rheumatology
Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies.
2012ArticleClinical and experimental rheumatology
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
2012ArticleJournal of Rheumatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Localisation des cabinets
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieux de consultation
SCP DES DRS BORDERIE BOURBON GROSJEAN LEBLAY ET GENTY
141 AVENUE PAUL BRINGUIER, 34080 Montpellier
Libéral© OpenStreetMap · Photos Wikimedia Commons (CC)SCP DES DRS BORDERIE BOURBON GROSJEAN LEBLAY ET GENTY
ZAE LES TANNES BASSES — 4 RUE DE MOURVEDRE, 34800 Clermont-l'Hérault
Libéral© OpenStreetMap
Tarifs & secteur de conventionnement
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis
Rheumatology (Oxford, England) · 2021
📚 35 citations🎯 RCR 3.70Top 12% NIH🩺 CliniqueLire l'abstract Crossref ↓
Abstract Objectives In RA, telemedicine may allow tight control of disease activity while reducing hospital visits. We developed a smartphone application connected with a physician’s interface to monitor RA patients. We aimed to assess the performance of this e-Health solution in comparison with routine practice in the management of patients with RA. Methods A six-month pragmatic, randomized, controlled, prospective, clinical trial was conducted in RA patients with high to moderate disease activity starting a new DMARD therapy. Two groups were established: ‘connected monitoring’ and ‘conventional monitoring’. The primary outcome was the number of physical visits between baseline and six months. Secondary outcomes included adherence, satisfaction, changes in clinical, functional and health status scores (Short-Form 12). Results Of the 94 randomized patients, 89 completed study: 44 in the ‘conventional monitoring’ arm and 45 in the ‘connected monitoring’ arm. The total number of physical visits between required baseline and six-month visits was significantly lower in the ‘connected monitoring’ group [0.42 (0.58) vs 1.93 (0.55); P <0.05]. No differences between groups were observed in the clinical and functional scores. A better quality of life for Short-Form 12 subscores (Role-Physical and Role-Emotional) were found in the ‘connected monitoring’ group. Conclusion Our results suggest that connected monitoring reduces the number of physical visits while maintaining a tight control of disease activity and improving quality of life in patients with RA starting a new treatment. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT03005925.
- 2Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies
Clinical and experimental rheumatology · 2012
📚 34 citations🎯 RCR 1.28
Publications scientifiques (12) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transversal4
▼
Transversal4
▼- Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for the self-assessment of rheumatoid arthritis disease activity
Rheumatology (Oxford, England) · 2016 · Evaluation Study
Espinoza F, Le Blay P, Coulon D, Lieu S, et al.
📚 28 cit.🎯 RCR 1.67🔬→🩺 Translationnel - An atypical sciatica revealing a rhabdomyolysis
Joint bone spine · 2014 · Case Reports
Croci-Torti A, Thouvenin Y, Le Blay P, Pers YM
- A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additional case of thalidomide efficiency
Joint bone spine · 2014 · Case Reports
Le Blay P, Rakotonirainy H, Lagier JC, Raoult D, et al.
📚 17 cit. - Acute inflammatory myalgia: think of myositis ossificans circumscripta
The Journal of rheumatology · 2013 · Case Reports
Galeano A, Fraison JB, Viala P, Le Blay P, et al.
📚 2 cit.
Fièvres auto-inflammatoires2
▼
Fièvres auto-inflammatoires2
▼- Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study
Arthritis care & research · 2017 · Journal Article
Kone-Paut I, Quartier P, Fain O, Grateau G, et al.
📚 11 cit.🩺 Clinique - Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study
Arthritis & rheumatology (Hoboken, N.J.) · 2015 · Journal Article
Houx L, Hachulla E, Kone-Paut I, Quartier P, et al.
📚 19 cit.🔬→🩺 Translationnel
Anti-TNF1
▼
Anti-TNF1
▼- Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials
The Journal of rheumatology · 2012 · Journal Article
LE Blay P, Mouterde G, Barnetche T, Morel J, et al.
📚 25 cit.🔬→🩺 Translationnel
Arthrite juvénile1
▼
Arthrite juvénile1
▼- Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis
Joint bone spine · 2017 · Journal Article
Pers YM, Le Blay P, Ludwig C, Rittore C, et al.
📚 14 cit.
Biothérapies non-anti-TNF1
▼
Biothérapies non-anti-TNF1
▼- Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
BMC rheumatology · 2020 · Journal Article
Ladhari C, Le Blay P, Vincent T, Larbi A, et al.
📚 2 cit.🔬→🩺 Translationnel
Épidémiologie & registres1
▼
Épidémiologie & registres1
▼- Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD
The Journal of rheumatology · 2017 · Journal Article
Espinoza F, Le Blay P, Combe B
📚 13 cit.
Essai clinique1
▼
Essai clinique1
▼- A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis
Rheumatology (Oxford, England) · 2021 · Comparative Study
Pers YM, Valsecchi V, Mura T, Aouinti S, et al.
📚 35 cit.🎯 RCR 3.70🩺 Clinique
Revue / méta-analyse1
▼
Revue / méta-analyse1
▼- Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies
Clinical and experimental rheumatology · 2012 · Journal Article
Le Blay P, Mouterde G, Barnetche T, Morel J, et al.
📚 34 cit.🎯 RCR 1.28🔬→🩺 Translationnel
Revue générale1
▼
Revue générale1
▼- Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies
Clinical and experimental rheumatology · 2012 · Journal Article
Le Blay P, Mouterde G, Barnetche T, Morel J, et al.
📚 34 cit.🎯 RCR 1.28🔬→🩺 Translationnel
